BIOMAT Database Logo BIOMAT Database Logo

A new regimen of interleukin 2 and lymphokine-activated killer cells. Efficacy without significant toxicity. 1988

T J Eberlein, and D D Schoof, and S E Jung, and D Davidson, and B Gramolini, and K McGrath, and A Massaro, and R E Wilson
Department of Surgery, Brigham & Women's Hospital, Boston, MA 02115.

Adoptive immunotherapy with high-dose interleukin 2 and lymphokine-activated killer (LAK) cells has proved to be successful in the treatment of some patients with metastatic cancer, but not without a significant degree of associated toxic effects. The primary goal of this study was to substantially reduce the toxicity of this complex and expensive treatment, while maintaining or improving efficacy. To this end, 29 patients were treated with LAK cells in conjunction with a low-dose regimen of interleukin 2 and a prolonged period of administration following LAK cell infusion. This protocol resulted in a considerable reduction in toxicity, as compared with that described in previous studies, without compromising the efficacy. This study offers further confirmation that adoptive immunotherapy of metastatic cancer can be clinically beneficial to patients for whom no other effective therapy is presently available.

UI MeSH Term Description Entries
D007376 Interleukin-2 A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes. IL-2,Lymphocyte Mitogenic Factor,T-Cell Growth Factor,TCGF,IL2,Interleukin II,Interleukine 2,RU 49637,RU-49637,Ro-23-6019,Ro-236019,T-Cell Stimulating Factor,Thymocyte Stimulating Factor,Interleukin 2,Mitogenic Factor, Lymphocyte,RU49637,Ro 23 6019,Ro 236019,Ro236019,T Cell Growth Factor,T Cell Stimulating Factor
D007694 Killer Cells, Natural Bone marrow-derived lymphocytes that possess cytotoxic properties, classically directed against transformed and virus-infected cells. Unlike T CELLS; and B CELLS; NK CELLS are not antigen specific. The cytotoxicity of natural killer cells is determined by the collective signaling of an array of inhibitory and stimulatory CELL SURFACE RECEPTORS. A subset of T-LYMPHOCYTES referred to as NATURAL KILLER T CELLS shares some of the properties of this cell type. NK Cells,Natural Killer Cells,Cell, NK,Cell, Natural Killer,Cells, NK,Cells, Natural Killer,Killer Cell, Natural,NK Cell,Natural Killer Cell
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D002985 Clinical Protocols Precise and detailed plans for the study of a medical or biomedical problem and/or plans for a regimen of therapy. Protocols, Clinical,Research Protocols, Clinical,Treatment Protocols,Clinical Protocol,Clinical Research Protocol,Clinical Research Protocols,Protocol, Clinical,Protocol, Clinical Research,Protocols, Clinical Research,Protocols, Treatment,Research Protocol, Clinical,Treatment Protocol
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

T J Eberlein, and D D Schoof, and S E Jung, and D Davidson, and B Gramolini, and K McGrath, and A Massaro, and R E Wilson
Toxicity of immunotherapy with interleukin-2 and lymphokine-activated killer cells.
January 1988, Pathology and immunopathology research,
T J Eberlein, and D D Schoof, and S E Jung, and D Davidson, and B Gramolini, and K McGrath, and A Massaro, and R E Wilson
Interleukin-2 and lymphokine activated killer cells: promises and cautions.
January 1989, Annals of clinical and laboratory science,
T J Eberlein, and D D Schoof, and S E Jung, and D Davidson, and B Gramolini, and K McGrath, and A Massaro, and R E Wilson
Interleukin 2 and lymphokine-activated killer cell therapy: analysis of a bolus interleukin 2 and a continuous infusion interleukin 2 regimen.
November 1990, Cancer research,
T J Eberlein, and D D Schoof, and S E Jung, and D Davidson, and B Gramolini, and K McGrath, and A Massaro, and R E Wilson
A regimen of surgical adjuvant immunotherapy for cancer with interleukin 2 and lymphokine-activated killer cells. Basis, clinical toxicity, and immunomodulatory effects.
January 1991, Biotherapy (Dordrecht, Netherlands),
T J Eberlein, and D D Schoof, and S E Jung, and D Davidson, and B Gramolini, and K McGrath, and A Massaro, and R E Wilson
Pulmonary toxicity of recombinant interleukin-2 plus lymphokine-activated killer cell therapy.
June 1993, The European respiratory journal,
T J Eberlein, and D D Schoof, and S E Jung, and D Davidson, and B Gramolini, and K McGrath, and A Massaro, and R E Wilson
Treatment of cancer with lymphokine-activated killer cells and interleukin-2.
October 1987, The New England journal of medicine,
T J Eberlein, and D D Schoof, and S E Jung, and D Davidson, and B Gramolini, and K McGrath, and A Massaro, and R E Wilson
Therapeutic uses of interleukin-2 and lymphokine-activated killer (LAK) cells.
June 1989, Blood reviews,
T J Eberlein, and D D Schoof, and S E Jung, and D Davidson, and B Gramolini, and K McGrath, and A Massaro, and R E Wilson
[Immunotherapy of tumors using interleukin-2 and lymphokine-activated killer cells].
February 1988, Schweizerische medizinische Wochenschrift,
T J Eberlein, and D D Schoof, and S E Jung, and D Davidson, and B Gramolini, and K McGrath, and A Massaro, and R E Wilson
The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo.
July 1985, Journal of immunology (Baltimore, Md. : 1950),
T J Eberlein, and D D Schoof, and S E Jung, and D Davidson, and B Gramolini, and K McGrath, and A Massaro, and R E Wilson
Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells.
June 1988, The New England journal of medicine,
Copied contents to your clipboard!